PLATINUM RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…
Matched conditions: PLATINUM RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control TerminatedThis study tested whether combining two immunotherapy drugs (SON-1010 and atezolizumab) could help control advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The trial involved 40 patients with advanced solid tumors, including those with platin…
Matched conditions: PLATINUM RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New pill tested as potential lifeline for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…
Matched conditions: PLATINUM RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for women battling Tough-to-Treat ovarian cancer?
Disease control TerminatedThis study tested an experimental drug called luveltamab tazevibulin against standard chemotherapy for women with advanced ovarian cancer that had returned and stopped responding to platinum-based drugs. It aimed to see if the new drug could better control the cancer and improve …
Matched conditions: PLATINUM RESISTANT OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC